A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
April 1, 2016
End Date
September 30, 2017
Administered By
Duke Cancer Institute
Awarded By
Janssen Research & Development, LLC
Start Date
April 1, 2016
End Date
September 30, 2017